Targeting IRES-Mediated p53 Synthesis for Cancer Diagnosis and Therapeutics

被引：20
|
作者：
Ji, Bai [1 ,2 ]
Harris, Benjamin R. E. [2 ]
Liu, Yahui [1 ]
Deng, Yibin [2 ,3 ]
Gradilone, Sergio A. [2 ,3 ]
Cleary, Margot P. [2 ,3 ]
Liu, Jianhua [1 ]
Yang, Da-Qing [2 ,3 ]
机构：
[1] Jilin Univ, Hosp 1, Dept Hepatobiliary & Pancreat Surg, Changchun 130021, Peoples R China
[2] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA
[3] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2017年 / 18卷 / 01期
关键词：
p53; internal ribosome entry site (IRES); DNA damage; IRES-trans acting factors (ITAFs); MESSENGER-RNA TRANSLATION; INITIATION-FACTOR EIF4E; RIBOSOME ENTRY SITES; DNA-DAMAGE; HELICASE-A; PROTEIN; MECHANISM; BREAST; BINDING; PARTICIPATION;
D O I：
10.3390/ijms18010093
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
While translational regulation of p53 by the internal ribosome entry site (IRES) at its 5'-untranslated region following DNA damage has been widely accepted, the detailed mechanism underlying the translational control of p53 by its IRES sequence is still poorly understood. In this review, we will focus on the latest progress in identifying novel regulatory proteins of the p53 IRES and in uncovering the functional connection between defective IRES-mediated p53 translation and tumorigenesis. We will also discuss how these findings may lead to a better understanding of the process of oncogenesis and open up new avenues for cancer diagnosis and therapeutics.
引用
收藏
页数：12
相关论文
共 50 条
  • [21] p53 and little brother p53/47: linking IRES activities with protein functions
    R Grover
    M M Candeias
    R Fåhraeus
    S Das
    Oncogene, 2009, 28 : 2766 - 2772
  • [22] p53 and little brother p53/47: linking IRES activities with protein functions
    Grover, R.
    Candeias, M. M.
    Fahraeus, R.
    Das, S.
    ONCOGENE, 2009, 28 (30) : 2766 - 2772
  • [23] Zinc metallochaperones for mutant p53 reactivation in cancer therapeutics
    Yu, Xin
    Na, Bing
    Zaman, Saif
    Withers, Tracy
    Gilleran, John
    Blayney, Alan J.
    Bencivenga, Anthony F.
    Blanden, Adam R.
    Liu, Yue
    Boothman, David A.
    Loh, Stewart N.
    Kimball, S. David
    Ganesan, Shridar
    Carpizo, Darren R.
    CANCER RESEARCH, 2020, 80 (16)
  • [24] The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and Promise
    Mandinova, Anna
    Lee, Sam W.
    SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (64)
  • [25] Effects of p53 on pancreatic cancer sensitivity to various therapeutics
    Steelman, Linda S.
    Abrams, Stephen L.
    Fitzgerald, Timothy L.
    Lertpiriyapong, Kvin
    Cocco, Lucio
    Martelli, Alberto M.
    Cervello, Melchiorre
    Montalto, Giuseppe
    Libra, Massimo
    LaHair, Michelle
    Franklin, Richard A.
    McCubrey, James A.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 38 : S13 - S13
  • [26] Glutaraldehyde (GLA) Loaded Albumin Nanoparticles Mediated p53 Targeting Cervical Cancer
    Zhou, Jianghong
    Zhang, Shuo
    Tao, Yin
    Wang, Jinjin
    Chen, Huan
    Zhou, Hong
    SCIENCE OF ADVANCED MATERIALS, 2021, 13 (08) : 1430 - 1436
  • [27] p53 translational control: A new facet of p53 regulation and its implication for tumorigenesis and cancer therapeutics
    Halaby, Marie-Jo
    Yang, Da-Qing
    GENE, 2007, 395 (1-2) : 1 - 7
  • [28] Targeting mutant p53 for efficient cancer therapy
    Bykov, Vladimir J. N.
    Eriksson, Sofi E.
    Bianchi, Julie
    Wiman, Klas G.
    NATURE REVIEWS CANCER, 2018, 18 (02) : 89 - 102
  • [29] Targeting mutant p53 in cancer: the latest insights
    Di Agostino, Silvia
    Fontemaggi, Giulia
    Strano, Sabrina
    Blandino, Giovanni
    D'Orazi, Gabriella
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
  • [30] Targeting mutant p53 stabilization for cancer therapy
    Wang, Jiajian
    Liu, Wenjun
    Zhang, Lanqing
    Zhang, Jihong
    FRONTIERS IN PHARMACOLOGY, 2023, 14
12345